CLLS vs. AMRN, AQST, PRTA, TERN, PRME, HUMA, SNDL, HRTX, AURA, and ALT
Should you be buying Cellectis stock or one of its competitors? The main competitors of Cellectis include Amarin (AMRN), Aquestive Therapeutics (AQST), Prothena (PRTA), Terns Pharmaceuticals (TERN), Prime Medicine (PRME), Humacyte (HUMA), SNDL (SNDL), Heron Therapeutics (HRTX), Aura Biosciences (AURA), and Altimmune (ALT). These companies are all part of the "pharmaceutical products" industry.
Cellectis vs. Its Competitors
Cellectis (NASDAQ:CLLS) and Amarin (NASDAQ:AMRN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.
Cellectis presently has a consensus target price of $4.00, indicating a potential upside of 146.15%. Amarin has a consensus target price of $12.00, indicating a potential downside of 30.76%. Given Cellectis' stronger consensus rating and higher probable upside, analysts clearly believe Cellectis is more favorable than Amarin.
Cellectis has higher earnings, but lower revenue than Amarin. Amarin is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.
In the previous week, Cellectis and Cellectis both had 1 articles in the media. Cellectis' average media sentiment score of 0.37 beat Amarin's score of -0.13 indicating that Cellectis is being referred to more favorably in the media.
63.9% of Cellectis shares are held by institutional investors. Comparatively, 22.3% of Amarin shares are held by institutional investors. 16.4% of Cellectis shares are held by insiders. Comparatively, 2.0% of Amarin shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Amarin has a net margin of -41.07% compared to Cellectis' net margin of -114.82%. Amarin's return on equity of -17.21% beat Cellectis' return on equity.
Cellectis has a beta of 2.91, meaning that its share price is 191% more volatile than the S&P 500. Comparatively, Amarin has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500.
Summary
Cellectis beats Amarin on 11 of the 15 factors compared between the two stocks.
Get Cellectis News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CLLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cellectis Competitors List
Related Companies and Tools
This page (NASDAQ:CLLS) was last updated on 7/9/2025 by MarketBeat.com Staff
